Get started
Author

Mark Maginn

Observed names: M MAGINN, M Maginn, M. Maginn
Observed institutions: University College Dublin, Lundbeck (Denmark), Ollscoil na Gaillimhe – University of Galway, AstraZeneca (Sweden), Crescendo Biologics Ltd. (United Kingdom), Biotrial (France)
ORCID: 0009-0007-9035-7298
Observed ORCID: 0009-0007-9035-7298
OpenAlex ID: A5008675421
Caffeine induces a profound and persistent tachycardia in response to MDMA (“Ecstasy”) administration
2006 · Ruth McNamara, Mark Maginn, et al. · European Journal of Pharmacology · 30
Adenosine A1 Receptor Blockade Mimics Caffeine's Attenuation of Ethanol‐Induced Motor Incoordination
2004 · Laura Connole, Andrew Harkin, et al. · Basic & Clinical Pharmacology & Toxicology · 30
PDF
The effect of 2-amino-3-phosphonopropionic acid (AP-3) in the gerbil model of cerebral ischaemia
1995 · Mark Maginn, Maeve Caldwell, et al. · European Journal of Pharmacology · 17
CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors
2024 · Sophie Archer, Phillip M. Brailey, et al. · Clinical Cancer Research · 15
PDF
Protective Effects of Vanoxeamine (GBR 12909) Against Ischaemia-Induced Hyperactivity and Neurodegeneration in the Gerbil Model of Cerebral Ischaemia
1997 · M Maginn, J.P Kelly, et al. · Pharmacology Biochemistry and Behavior · 11
Evaluation of NTP42, a novel thromboxane receptor antagonist, in a first-in-human phase I clinical trial
2023 · Helen M. Reid, Mark Maginn, et al. · Frontiers in Pharmacology · 5
PDF
Preclinical Evaluation of an Engineered AAV Capsid in Non-Human Primates for the Treatment of Haemophilia B
2018 · Allison Dane, Jenny McIntosh, et al. · Blood · 4
Effect of brain microdialysis on aminergic transmitter levels in repeated cerebral global transient ischemia in rat
1996 · Seddik Thaminy, Eric Bellissant, et al. · Journal of Neuroscience Methods · 2
Abstract CT206: A phase I open-label, dose escalation and expansion trial to investigate the safety, pharmacokinetics and pharmacodynamics of CB307, a trispecific Humabody T-cell enhancer, in patients with PSMA+ advanced and/or metastatic solid tumors (POTENTIA)
2021 · Kenji Hashimoto, Andrew J. Pierce, et al. · Cancer Research · 1
Metabotropic and Ionotropic Receptor Antagonists Prevent the Neurodegeneration Seen Following 5 Min Bilateral Carotid Occlusion in the Mongolian Gerbil Model of Cerebral Ischaemia
1995 · M MAGINN, M CALDWELL, et al. · Behavioural Pharmacology · 1
Supplementary Figure 8 from CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors
2024 · Sophie Archer, Phillip M. Brailey, et al.
Supplementary Figure 9 from CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors
2024 · Sophie Archer, Phillip M. Brailey, et al.
Supplementary Figure 10 from CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors
2024 · Sophie Archer, Phillip M. Brailey, et al.
Data from CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors
2024 · Sophie Archer, Phillip M. Brailey, et al.
Supplemental Methods 1 from CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors
2024 · Sophie Archer, Phillip M. Brailey, et al.
Supplementary Figure 3 from CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors
2024 · Sophie Archer, Phillip M. Brailey, et al.
Supplementary Figure 11 from CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors
2024 · Sophie Archer, Phillip M. Brailey, et al.
Supplementary Figure 5 from CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors
2024 · Sophie Archer, Phillip M. Brailey, et al.
Supplementary Figure 1 from CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors
2024 · Sophie Archer, Phillip M. Brailey, et al.
Supplementary Figure 7 from CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors
2024 · Sophie Archer, Phillip M. Brailey, et al.
Supplementary Figure 1 from CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors
2024 · Sophie Archer, Phillip M. Brailey, et al.
Data from CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors
2024 · Sophie Archer, Phillip M. Brailey, et al.
Supplementary Video 1 from CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors
2024 · Sophie Archer, Phillip M. Brailey, et al.
Supplementary Figure 7 from CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors
2024 · Sophie Archer, Phillip M. Brailey, et al.
Supplementary Table 1 from CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors
2024 · Sophie Archer, Phillip M. Brailey, et al.
Works count: 33
Citation count: 116
H-index: 5
I10-index: 5
Year
Topic
Type